Channel Therapeutics Corporation
CHRO · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $3 | $0 | $0 |
| Gross Profit | $0 | -$3 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1 | $3 | $0 | $0 |
| G&A Expenses | $6 | $4 | $2 | $1 |
| SG&A Expenses | $6 | $4 | $2 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $8 | $7 | $2 | $1 |
| Operating Income | -$8 | -$7 | -$2 | -$1 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$0 | -$1 | -$0 | $0 |
| Pre-Tax Income | -$8 | -$7 | -$2 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8 | -$7 | -$2 | -$1 |
| % Margin | – | – | – | – |
| EPS | -1.43 | -1.28 | -0.43 | -0.1 |
| % Growth | -11.7% | -197.7% | -330% | – |
| EPS Diluted | -1.43 | -1.28 | -0.43 | -0.1 |
| Weighted Avg Shares Out | 6 | 6 | 6 | 6 |
| Weighted Avg Shares Out Dil | 6 | 6 | 6 | 6 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | -$1 | $1 | $0 | $0 |
| Depreciation & Amortization | $1 | $0 | $1 | $1 |
| EBITDA | -$8 | -$7 | -$2 | $0 |
| % Margin | – | – | – | – |